Enteric neuropathies exist as a wide range of human disorders, impacting variably on the gastrointestinal (GI) tract, including a number of severe motility disorders such as achalasia, 1,2 gastroparesis, 3,4 and slow transit constipation. 5-7 Such conditions can arise from disruption of the development of the enteric nervous system (ENS) or through acquired processes, which lead to neuronal loss or the disturbance of specific neuronal signaling. Hirschsprung 
| INTRODUC TI ON
Enteric neuropathies exist as a wide range of human disorders, impacting variably on the gastrointestinal (GI) tract, including a number of severe motility disorders such as achalasia, 1,2 gastroparesis, 3, 4 and slow transit constipation. [5] [6] [7] Such conditions can arise from disruption of the development of the enteric nervous system (ENS) or through acquired processes, which lead to neuronal loss or the disturbance of specific neuronal signaling. Hirschsprung disease (HSCR) is one of the best characterized congenital enteric neuropathies, resulting from absence of ENS formation in a variable region of the colon, 8 which reflects a failure of the original ENS precursors to complete rostro-caudal colonization of the developing GI tract. The absence of the ENS in HSCR patients results in constriction of the terminal aganglionic intestine from unopposed tonic muscle contraction, causing blockage and associated distention of the proximal intestine. 9 Current therapeutic intervention, in such cases, is limited to surgical resection of the aganglionic region. Unfortunately, in a significant proportion of HSCR patients such interventions have a significant morbidity 10, 11 and overall poor long-term prognosis, with patients often requiring further surgical management through early childhood and adolescence. Beyond HSCR, the failure of currently available surgical techniques to provide a curative treatment across a variety of motility disorders underlines the need for alternative approaches to treat these devastating diseases.
This need, coupled with advances in our understanding of the underlying genetic and cellular elements involved in the development of the ENS have provided the impetus to investigate potential cell-based therapies as a means of replacing neurons which have been lost via disease processes or are absent through failures in development, in a range of GI disease models.
| IDENTIFI C ATI ON AND ISOL ATI ON OF ENTERI C NEUR AL S TEM CELL S
The ENS is derived principally from a population of vagal neural crest-derived cells, which enter the foregut in humans at approximately embryonic week 4 (mice at approx. E9.5) 12, 13 and migrate in a rostro-caudal fashion to colonize the entire gut by approximately gestational week 7 in humans 13 or E13.5 in mice. 14 A smaller contribution to the ENS is attributed to a sacral neural crest cell (NCC) population, in mouse and avian models (and presumably in humans), which appear to enter the terminal colon and migrate to colonize this terminal region in an anal-to-oral fashion. 15, 16 In order to fully colonize the expanding gut during embryonic development, vagal and sacral NCCs are required to both proliferate and migrate extensively. Elegant imaging studies have allowed for visualization of these processes 17, 18 demonstrating the migration of NCCs in chains with highly dynamic migratory patterns, including "trans-mesenteric" migration of enteric NCCs in the colonization of the mouse colon. 19 This migratory pattern is highly dependent on several signaling pathways, which have been reviewed in detail elsewhere [20] [21] [22] [23] and as such are outside of the scope of this current review.
Of significant interest is the ability of the migratory enteric neural crest to colonize the expanding gut in terms of cell numbers. In order to enable full colonization, it is clear that a significant proliferative capacity is required to expand the relatively small population of pioneer neural crest cells entering the foregut to ultimately lead to the formation of the largest branch of the peripheral nervous system incorporating 200-600 million enteric neurons and glia. 24 This process is tightly coordinated by Ret/ GDNF signaling 25 with the enteric NCCs undergoing significant expansion along the length of the developing gut. 26 . Additionally, early studies by Bondurand et al. highlighted the critical role of SOX10 and endothelin 3 signaling in the maintenance of multilineage ENS progenitors. 27 The proliferative capacity and mul- 
Key Points
• Autologously derived enteric neural stem cells (ENSC) are a possible treatment option for enteric neuropathies.
• ENSC have been shown to functionally integrate and rescue function in animal models of intestinal disease.
• Further studies are required to fully understand the mechanisms of ENSC rescue before this exciting cellular therapy can be applied clinically.
patients aged up to 84 years old 31 suggesting that multipotent ENS promoter (R26-hPAP) migrate to the gut, localizing to the proximity of the submucosal and myenteric ganglia and appropriately differentiate to neurons and glial cell lineages. 46 Similarly, unsorted murine ENSC isolated from postnatal Actb-DSRed intestine, 41 Hence, it is likely that future studies will need to assess colonization of target organs in a more detailed fashion at the microscopic level, rather than relying solely on stereoscopic live imaging techniques. 
| TR AN S PL ANTATI ON OF ENTERI C NEUR AL S TEM CELL S TO G ANG LI ONI C COLON

| TR AN S PL ANTATI ON OF ENTERI C NEUR AL S TEM CELL S TO D IS E A S E MODEL S
| ALTERNATIVE CELLUL AR SOURCE S FOR THE TRE ATMENT OF ENTERI C NEUROPATHIE S
Together with preliminary studies of ENSC demonstrating the potential of an autologous stem cell therapy to rescue patho- 
| FUTURE CHALLENG E S FOR ENTERIC NEUR AL S TEM CELL THER APEUTI C S
Many of the challenges which will be required for translational therapy of ENSC for use in the clinic, including harmonization of protocols and approaches across multiple research groups and centers, have been outlined in a major white paper from leaders in the field. rather than in peripheral organs including the mesentery, which might be expected if a vascular migration phenomenon did exist. In order to progress toward possible clinical application of ENSC it will therefore be necessary to further investigate the exact migration pathways of donor ENSC in order to circumvent off-target engraftment.
More pertinent are the possible non-cell-autonomous effects, which transplanted ENSC may exert on the host microenvironment.
Our recent work demonstrated that in vivo transplantation of ENSC into an nNOS-deficient microenvironment led to the development of nNOS + neurons. Unexpectedly, we also observed significant increases in ICC numbers throughout the colon of these mice, 51 results which appear consistent with observations of transcriptomic alteration after ENS incorporation within human intestinal organoid units. 57 It is now clear that a much more detailed understanding of the effects that transplanted ENSC, be that gut or pluripotent-derived, have on the host neuromusculature is required. It is also apparent that our current understanding and phenotyping of gut motility disorders in terms of cellular or functional pathology is lacking, and future studies will be required to redress these issues in order to proceed toward clinical translation. 
| CON CLUS IONS
The past decades have seen a significant increase in our ability to isolate and manipulate stem cells for the treatment of enteric neuropathies. Our current understanding of ENSC offers promise of a potential autologous cell source, which may benefit a number of disease areas. However, in order to realize this potential, future studies are required to ascertain transplanted cell dynamics and the effects of transplantation on the host microenvironment. These studies, in addition to improved and more efficient protocols for the isolation of postnatal human ENSC, are fundamental priorities before this exciting cellular therapy can be translated to first-in-man studies.
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